TB 500 Thymosin Beta 4 10mg – Protide Health USA

TB 500 Thymosin Beta 4 Overview & Technical Specifications

TB 500 thymosin beta 4 in this Protide Health product refers specifically to the full-length 43-amino-acid form of thymosin beta-4 rather than a shorter peptide fragment.

Its sequence is:

Ac-Ser-Asp-Lys-Pro-Asp-Met-Ala-Glu-Ile-Glu-Lys-Phe-Asp-Lys-Ser-Lys-Leu-Lys-Lys-Thr-Glu-Thr-Gln-Glu-Lys-Asn-Pro-Leu-Pro-Ser-Lys-Glu-Thr-Ile-Glu-Gln-Glu-Lys-Gln-Ala-Gly-Glu-Ser

The supplied thymosin beta-4 PubChem chemical record identifies the full-length compound as PubChem CID 16132341 with CAS number 77591-33-4 and molecular formula C212H350N56O78S.

Protide Health supplies the peptide as 10mg of 99% purity lyophilized material intended for controlled biochemical, cytoskeletal, molecular, cellular, analytical, and qualified preclinical experimentation.

Technical Specifications

• Product Name: TB-500 / Thymosin Beta-4
• Chemical Identity: Full-length N-acetylated thymosin beta-4
• Quantity: 10mg
• Vial Size: 3mL
• Form: Lyophilized powder
• Purity: 99%
• Testing: HPLC-MS verified; third-party tested
• Peptide Length: 43 amino acids
• CAS Number: 77591-33-4
• PubChem CID: 16132341
• Molecular Formula: C212H350N56O78S
• Molecular Weight: Approximately 4963.5 g/mol
• Appearance: White to off-white lyophilized powder
• Solubility: Soluble in water
• Storage: Store sealed at ≤6°C and protected from heat, light, and moisture
• Research Use: Biochemical, cytoskeletal, molecular, cellular, and preclinical research only

TB 500 Thymosin Beta 4 Mechanism & Research Context

The best-characterized molecular function of full-length thymosin beta-4 is its interaction with monomeric G-actin.

Beta-thymosins act as intracellular actin-sequestering peptides. Thymosin beta-4 can bind G-actin in approximately a 1:1 complex and influence the available intracellular pool of actin monomers used in cytoskeletal remodeling.

Research has therefore examined TB 500 thymosin beta 4 in relation to:

• G-actin binding
• Actin polymerization dynamics
• Cytoskeletal organization
• Cell migration
• Endothelial-cell behavior
• Vascular-development pathways
• Cellular differentiation
• Extracellular signaling hypotheses

Researchers can review broader thymosin beta-4 research indexed by PubMed for peer-reviewed literature covering actin biology and other experimental pathways.

Thymosin beta-4 research spans biochemical assays, cultured cells, animal models, and some studies involving pharmaceutical preparations. Findings from those settings should not automatically be attributed to independently supplied laboratory material.

Preclinical Research Applications

G-Actin Sequestration Research

The most established biochemical role of thymosin beta-4 is its interaction with actin.

Studies have shown that the peptide forms a complex with monomeric G-actin and can suppress polymerization into filamentous F-actin under appropriate experimental conditions.

This gives TB 500 thymosin beta 4 particular relevance to research involving:

• Actin dynamics
• Cytoskeletal remodeling
• Cell morphology
• Cell migration
• Intracellular actin buffering
• Protein–protein interactions

A review of beta-thymosin biology describes thymosin beta-4 as one of the major intracellular G-actin-sequestering peptides in vertebrate cells.

Cell Migration Research

Actin remodeling is fundamental to cellular movement.

Because thymosin beta-4 influences the intracellular pool of monomeric actin, researchers have investigated its relationship with endothelial-cell, epithelial-cell, keratinocyte, and other cellular migration systems.

These experiments provide mechanistic context for cell-motility research but do not establish therapeutic outcomes for this Protide Health product.

Vascular and Angiogenesis Research

Preclinical literature has also investigated thymosin beta-4 in vascular models.

Research has examined processes including:

• Endothelial-cell migration
• Capillary formation
• Angiogenesis
• Vasculogenesis
• Arteriogenesis
• Pericyte recruitment
• Extracellular-matrix remodeling

Reviews describe multiple vascular roles for thymosin beta-4, while also noting that several underlying molecular mechanisms remain incompletely understood.

Cytoskeletal Structure-Activity Research

The actin-binding activity of thymosin beta-4 depends on particular regions of its sequence.

Experimental studies comparing full-length peptide with fragments have demonstrated that truncated sequences do not necessarily preserve the same G-actin-sequestering capability.

This is an especially important consideration for TB 500 thymosin beta 4, because the terms “TB-500” and “thymosin beta-4” are sometimes used interchangeably commercially despite documented chemical differences between full-length Tβ4 and shorter fragments.

Thymosin Beta 4 vs TB 500: Important Chemical Distinction

The phrase thymosin beta 4 vs tb 500 requires careful definition.

Full-length thymosin beta-4 is the 43-amino-acid N-acetylated peptide described on this page.

In contrast, a published analytical study investigating material marketed as TB-500 identified an N-terminally acetylated seven-residue fragment corresponding to thymosin beta-4 residues 17–23:

Ac-Lys-Leu-Lys-Lys-Thr-Glu-Thr-Gln, commonly represented as Ac-LKKTETQ.

Therefore, the commercial term TB-500 does not always identify the same chemical substance across suppliers and literature.

For this Protide Health listing, TB 500 thymosin beta 4 specifically refers to the supplied full-length 43-amino-acid thymosin beta-4 material characterized by CAS 77591-33-4 and PubChem CID 16132341.

What Research on Thymosin Beta 4 Benefits Actually Shows

Searches for thymosin beta 4 benefits frequently present broad claims that extend beyond what a research product page should establish.

Published laboratory and preclinical literature has investigated experimentally measurable endpoints involving:

• G-actin sequestration
• Cytoskeletal regulation
• Cellular migration
• Endothelial-cell signaling
• Angiogenesis-associated pathways
• Tissue-response mechanisms
• Cellular differentiation
• Inflammatory signaling

Some literature has also investigated thymosin beta-4 in animal injury models and pharmaceutical clinical-development settings. Those findings concern specific experimental preparations and study designs and do not establish health benefits for this research vial.

Accordingly, TB 500 thymosin beta 4 should be evaluated through defined biochemical and preclinical endpoints rather than therapeutic claims.

Full-Length Thymosin Beta-4 Research

The full-length peptide contains a central actin-binding region that includes the LKKTETQ motif.

Research indicates that sequence context matters. Experiments with various thymosin beta-4 fragments found that removal of significant portions of the N-terminal region could reduce or eliminate G-actin-sequestering activity.

This reinforces the importance of distinguishing the full-length 43-residue peptide from smaller fragments when interpreting experimental literature.

Research Format and Storage

Protide Health supplies TB 500 thymosin beta 4 as white to off-white lyophilized powder in a 3mL vial.

Lyophilization creates a dry research format by removing water from frozen material under reduced pressure.

According to the supplied product specification:

• Store sealed at ≤6°C
• Protect from heat
• Protect from direct light
• Protect from moisture

The material is specified as soluble in water.

No human administration, injection, dosing, treatment, or preparation instructions are provided.

Thymosin Beta 4 Dosage Searches and Laboratory Use

The phrase thymosin beta 4 dosage relates to human or veterinary administration and is not applicable to this laboratory research product.

The stated 10mg quantity represents the amount of research material contained in the vial. It is not a recommended dose.

Protide Health does not provide human dosing schedules, injection protocols, cycles, administration instructions, or treatment recommendations.

Thymosin Beta 4 Capsules

This product is not supplied as thymosin beta 4 capsules.

It is provided as 10mg of lyophilized laboratory research material in a 3mL vial and is not marketed as an oral supplement, pharmaceutical dosage form, or other human-use preparation.

Research Limitations

Research involving TB 500 thymosin beta 4 requires several important distinctions:

• Full-length thymosin beta-4 and shorter TB-500 fragments are chemically different.
• Evidence from one molecular form should not automatically be applied to another.
• Actin-binding studies establish biochemical mechanisms, not medical efficacy.
• Cellular findings cannot automatically be extrapolated to intact organisms.
• Animal studies cannot establish equivalent human outcomes.
• Studies involving pharmaceutical thymosin beta-4 preparations do not validate an independently supplied research product.
• Angiogenesis and cellular-migration findings are highly dependent on model and experimental conditions.
• Several proposed extracellular signaling mechanisms remain incompletely characterized.

These limitations are essential when interpreting the broader thymosin beta-4 literature.

Literature & Citation Index

Thymosin Beta4: Actin-Sequestering Protein Moonlights to Repair Injured Tissues

Authors: Allan L. Goldstein, Ewald Hannappel, Hynda K. Kleinman
Journal: Trends in Molecular Medicine
Year: 2005
PMID: 16099219
DOI: 10.1016/j.molmed.2005.07.004
Research Context: G-actin sequestration and broader molecular biology of full-length thymosin beta-4.

Beta-Thymosins

PMID: 17468232
Research Context: Discovery, intracellular distribution, G-actin sequestration, and biological functions of beta-thymosins.

Actin-Sequestering Ability of Thymosin Beta-4 and Its Fragments

PMID: 8471179
Research Context: Comparison of full-length thymosin beta-4 with peptide fragments in G-actin polymerization assays.

Synthesis and Characterization of the N-Terminal Acetylated 17-23 Fragment of Thymosin Beta-4 Identified in TB-500

Authors: Simone Esposito et al.
Journal: Drug Testing and Analysis
Year: 2012
PMID: 22962027
DOI: 10.1002/dta.1402
Research Context: Analytical identification of Ac-LKKTETQ in material marketed as TB-500.

Thymosin Beta4 and the Vasculature

PMID: 30063849
Research Context: Vascular development, endothelial migration, angiogenesis, arteriogenesis, and extracellular-matrix research.

Related Protide Health Research Products

Researchers examining other peptide-signaling systems can review the CJC-1295 No DAC & Ipamorelin Blend for a distinct endocrine-signaling research model.

The GHK-Cu & KPV Blend provides a separate multi-peptide research formulation involving copper-peptide and KPV-associated pathways.

Researchers can also examine the Glow Blend GHK-Cu, BPC-157 & TB-500 when comparing multi-component peptide research materials.

These products contain different compounds and should not be considered chemically or mechanistically interchangeable.

Frequently Asked Questions

What is TB 500 Thymosin Beta 4?

TB 500 thymosin beta 4 on this Protide Health page refers to full-length N-acetylated thymosin beta-4, a 43-amino-acid actin-binding research peptide.

What is the sequence of full-length thymosin beta-4?

The sequence is:

Ac-SDKPDMAEIEKFDKSKLKKTETQEKNP LPSKETIEQEKQAGES

Written without spacing:

Ac-SDKPDMAEIEKFDKSKLKKTETQEK NPLPSKETIEQEKQAGES

The peptide contains 43 amino-acid residues.

What is the primary molecular function studied with thymosin beta-4?

Its best-established biochemical function is binding and sequestration of monomeric G-actin, thereby participating in regulation of the intracellular actin pool.

Is TB-500 identical to full-length thymosin beta-4?

Not necessarily. Published chemical analysis has identified material marketed as TB-500 as the shorter Ac-LKKTETQ thymosin beta-4 fragment. The Protide Health product specification on this page instead identifies full-length 43-residue thymosin beta-4.

What does thymosin beta 4 vs TB 500 mean?

The comparison usually concerns nomenclature and molecular identity. Full-length thymosin beta-4 contains 43 amino acids, while some scientifically analyzed TB-500 material has consisted of an acetylated seven-residue fragment derived from thymosin beta-4.

What does research say about thymosin beta 4 benefits?

Research has investigated actin regulation, cellular migration, vascular pathways, angiogenesis, cytoskeletal remodeling, and related processes. These experimental findings should not be interpreted as established therapeutic benefits of this laboratory product.

What purity does Protide Health specify?

The supplied product specification states 99% purity, with HPLC-MS verification and third-party testing.

What form is the product supplied in?

The TB 500 thymosin beta 4 product is supplied as 10mg of white to off-white lyophilized powder in a 3mL vial.

Is the product intended for human use?

No. It is supplied exclusively for biochemical analysis, molecular research, cell-based studies, analytical testing, and qualified preclinical experimentation.

Laboratory Terms & Compliance

Laboratory Research Use Only

This product is supplied exclusively for laboratory research, analytical testing, in-vitro studies, preclinical research, and qualified scientific experimentation.

It is not intended for human or veterinary consumption, diagnostic use, medical use, therapeutic use, tissue-healing treatment, athletic-performance enhancement, bodybuilding, or clinical administration.

No human dosage, dosing, injection, administration, cycle, treatment, or preparation instructions are provided.

The purchaser is responsible for appropriate laboratory handling, storage, and use in accordance with applicable institutional, federal, state, and local requirements.

For research use only.